205 related articles for article (PubMed ID: 37795982)
1. A broadly immunogenic polyvalent
Li S; Anvari S; Ptacek G; Upadhyay I; Kaminski RW; Sack DA; Zhang W
Infect Immun; 2023 Nov; 91(11):e0031623. PubMed ID: 37795982
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Functional B-Cell Epitopes at the Amino Terminus of
Li S; Han X; Upadhyay I; Zhang W
Appl Environ Microbiol; 2022 Aug; 88(15):e0038422. PubMed ID: 35856689
[No Abstract] [Full Text] [Related]
3. Polyvalent Protein Adhesin MEFA-II Induces Functional Antibodies against Enterotoxigenic Escherichia coli (ETEC) Adhesins CS7, CS12, CS14, CS17, and CS21 and Heat-Stable Toxin (STa).
Upadhyay I; Parvej SMD; Li S; Lauder KL; Shen Y; Zhang W
Appl Environ Microbiol; 2023 Jun; 89(6):e0068323. PubMed ID: 37212687
[TBL] [Abstract][Full Text] [Related]
4. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.
Heine SJ; Diaz-McNair J; Andar AU; Drachenberg CB; van de Verg L; Walker R; Picking WL; Pasetti MF
J Immunol; 2014 Feb; 192(4):1630-40. PubMed ID: 24453241
[TBL] [Abstract][Full Text] [Related]
5. MecVax supplemented with CFA MEFA-II induces functional antibodies against 12 adhesins (CFA/I, CS1-CS7, CS12, CS14, CS17, and CS21) and 2 toxins (STa, LT) of enterotoxigenic
Zhang C; Li S; Upadhyay I; Lauder KL; Sack DA; Zhang W
Microbiol Spectr; 2024 Apr; 12(4):e0415323. PubMed ID: 38364078
[TBL] [Abstract][Full Text] [Related]
6. Application of a Novel Epitope- and Structure-Based Vaccinology-Assisted Fimbria-Toxin Multiepitope Fusion Antigen of Enterotoxigenic Escherichia coli for Development of Multivalent Vaccines against Porcine Postweaning Diarrhea.
Lu T; Moxley RA; Zhang W
Appl Environ Microbiol; 2020 Nov; 86(24):. PubMed ID: 32144103
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Oaks EV; Turbyfill KR
Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
[TBL] [Abstract][Full Text] [Related]
8. Development of recombinant vaccine candidate molecule against Shigella infection.
Chitradevi STS; Kaur G; Sivaramakrishna U; Singh D; Bansal A
Vaccine; 2016 Oct; 34(44):5376-5383. PubMed ID: 27591952
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.
Heine SJ; Diaz-McNair J; Martinez-Becerra FJ; Choudhari SP; Clements JD; Picking WL; Pasetti MF
Vaccine; 2013 Jun; 31(28):2919-29. PubMed ID: 23644075
[TBL] [Abstract][Full Text] [Related]
10. Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
Martinez-Becerra FJ; Kissmann JM; Diaz-McNair J; Choudhari SP; Quick AM; Mellado-Sanchez G; Clements JD; Pasetti MF; Picking WL
Infect Immun; 2012 Mar; 80(3):1222-31. PubMed ID: 22202122
[TBL] [Abstract][Full Text] [Related]
11. Immunization of Rabbits with a Quadrivalent
Odundo EA; Weerts HP; Musila L; Ogonda L; Dreyer AM; Schneider J; Carranza P; Kaminski RW
mSphere; 2022 Jun; 7(3):e0102021. PubMed ID: 35611657
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Characterization of Immunogenicity and Efficacy against Diarrhea from MecVax, a Multivalent Enterotoxigenic E. coli Vaccine Candidate.
Seo H; Garcia C; Ruan X; Duan Q; Sack DA; Zhang W
Infect Immun; 2021 Jun; 89(7):e0010621. PubMed ID: 33875477
[TBL] [Abstract][Full Text] [Related]
13. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.
Kaminski RW; Wu M; Turbyfill KR; Clarkson K; Tai B; Bourgeois AL; Van De Verg LL; Walker RI; Oaks EV
Clin Vaccine Immunol; 2014 Mar; 21(3):366-82. PubMed ID: 24403527
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.
Martinez-Becerra FJ; Chen X; Dickenson NE; Choudhari SP; Harrison K; Clements JD; Picking WD; Van De Verg LL; Walker RI; Picking WL
Infect Immun; 2013 Dec; 81(12):4470-7. PubMed ID: 24060976
[TBL] [Abstract][Full Text] [Related]
15. A Novel
Desalegn G; Kapoor N; Pill-Pepe L; Bautista L; Yin L; Ndungo E; Oaks EV; Fairman J; Pasetti MF
mSphere; 2023 Jun; 8(3):e0001923. PubMed ID: 37017547
[No Abstract] [Full Text] [Related]
16. Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice.
Heine SJ; Franco-Mahecha OL; Chen X; Choudhari S; Blackwelder WC; van Roosmalen ML; Leenhouts K; Picking WL; Pasetti MF
Immunol Cell Biol; 2015 Aug; 93(7):641-52. PubMed ID: 25776843
[TBL] [Abstract][Full Text] [Related]
17. Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes.
Citiulo F; Necchi F; Mancini F; Rossi O; Aruta MG; Gasperini G; Alfini R; Rondini S; Micoli F; Rappuoli R; Saul A; Martin LB
PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009826. PubMed ID: 34644291
[TBL] [Abstract][Full Text] [Related]
18. Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine.
Venkatesan MM; Hartman AB; Newland JW; Ivanova VS; Hale TL; McDonough M; Butterton J
Infect Immun; 2002 Jun; 70(6):2950-8. PubMed ID: 12010984
[TBL] [Abstract][Full Text] [Related]
19. Intradermally Administered Enterotoxigenic Escherichia coli Vaccine Candidate MecVax Induces Functional Serum Immunoglobulin G Antibodies against Seven Adhesins (CFA/I and CS1 through CS6) and Both Toxins (STa and LT).
Garcia CY; Seo H; Sack DA; Zhang W
Appl Environ Microbiol; 2022 Feb; 88(4):e0213921. PubMed ID: 34936832
[TBL] [Abstract][Full Text] [Related]
20.
Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
[No Abstract] [Full Text] [Related]
[Next] [New Search]
